RGD Reference Report - Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3.

Authors: Ueda, K  Yamada, K  Urashima, M  Ishibashi, Y  Shirai, M  Nikaido, T  Takahashi, H  Okamoto, A  Saito, M  Yasuda, M  Ohkawa, K  Tanaka, T 
Citation: Ueda K, etal., Oncol Rep. 2007 Apr;17(4):731-5.
RGD ID: 2296029
Pubmed: PMID:17342307   (View Abstract at PubMed)

Extracellular matrix metalloproteinase inducer (EMMPRIN) is a member of the immunoglobulin superfamily of adhesion molecules and has a role in the activation of several matrix metalloproteinases (MMPs). We evaluated whether EMMPRIN expression is related to tumor progression and patient outcome in human endometrial carcinoma. Paraffin-embedded surgical tissue samples from 112 patients with endometrial carcinoma were stained with anti-EMMPRIN antibody (monoclonal antibody 12C3:MoAb 12C3) for immunohistochemical analysis. EMMPRIN protein was expressed in cancerous lesions with the incidence of 97.3% (109 of 112 cases), but not in normal lesions. The scores determined by the combination of intensity and pattern of EMMPRIN staining in cancer cells correlated significantly with various histopathological risk factors: advanced stage, P=0.001; poorly differentiated carcinoma, P<0.001; lymph node metastasis, P=0.002; and lymphatic vessel infiltration, P=0.027. More importantly, recurrence-free survival was shortened in patients with higher EMMPRIN scores (HR, 3.08; 95% CI, 1.32-7.19; P=0.01). These results suggest that measurement of EMMPRIN expression with simple immunohistochemical staining may enhance the understanding of the pathophysiology of endometrial carcinoma.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
endometrial carcinoma disease_progressionIEP 2296029protein:increased expression:endometriumRGD 
endometrial carcinoma disease_progressionISOBSG (Homo sapiens)2296029; 2296029protein:increased expression:endometriumRGD 

Objects Annotated

Genes (Rattus norvegicus)
Bsg  (basigin (Ok blood group))

Genes (Mus musculus)
Bsg  (basigin)

Genes (Homo sapiens)
BSG  (basigin (Ok blood group))


Additional Information